ethyl 1,4-dihydroxy-6-(6-methoxypyridin-2-yl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 1,4-dihydroxy-6-(6-methoxypyridin-2-yl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate
• 英文别名: Ethyl 1,4-dihydroxy-6-(6-methoxypyridin-2-yl)-2-oxo-1,8-naphthyridine-3-carboxylate；ethyl 1,4-dihydroxy-6-(6-methoxypyridin-2-yl)-2-oxo-1,8-naphthyridine-3-carboxylate
• 化学式: C₁₇H₁₅N₃O₆
• 分子量: 357.323
• InChiKey: SEIVECXTELRBJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• THROMBOPOIETIN MIMETICS
  申请人：GlaxoSmithKline LLC

  公开号：US20150093356A1

  公开（公告）日：2015-04-02

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新型工艺和中间体。还发明了一种治疗血小板减少症的方法，包括在需要的哺乳动物（包括人类）中给予所选的羟基-1-偶氮苯衍生物的有效量。
• COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES
  申请人：The Trustees of the University of Pennsylvania

  公开号：US20150094327A1

  公开（公告）日：2015-04-02

  The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase's DNA cleavage activity. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs thereof. In certain embodiments, the compounds of the invention are useful to treat a poxvirus infection in an infected subject.
• [EN] COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES<br/>[FR] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE RÉSOLVASES
  申请人：UNIV PENNSYLVANIA

  公开号：WO2013165898A2

  公开（公告）日：2013-11-07

  The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase-DNA cleavage. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs of the inhibitors. The compositions of the invention may be used to treat a poxvirus infection.